

# Review: molecular basis of MNS blood group variants

P. PALACAJORNSUK

The MNS blood group antigens are expressed in the RBC membrane on glycophorin A (GPA), glycoprotein B (GPB), or combinations of both. GPA expresses the M or N antigen, whereas GPB expresses the S or s antigen and the N antigen (N<sup>s</sup>). Both glycoprotein genes (*GYP A* and *GYP B*) are located on the long arm of chromosome 4 and share 95 percent sequence identity. This high degree of sequence identity, together with the rare involvement of a third homologous gene (*GYPE*), provides an increased chance of recombination, resulting in hybrid molecules that often carry one or more novel antigens. Some of the antigens in the MNS system result from a single nucleotide substitution. The MNS blood group system now consists of more than 40 distinct antigens. This review summarizes the molecular basis associated with some of the antigens in the MNS blood group system. *Immunohematology* 2006;22:171–182.

**Key Words:** MNS blood group, MNS antigens, glycoprotein genes, hybrid glycoproteins, genetic mechanism, molecular basis

## MNS Blood Group System

The MNS blood group system was the second blood group system to be discovered.<sup>1</sup> The MNS antigens are carried on glycoprotein A (GPA), glycoprotein B (GPB), or hybrids of GPA and GPB, and are fully developed at birth. Currently, this blood group system consists of more than 40 distinct antigens (Table 1), and is second only to the Rh blood group system in its complexity.<sup>2</sup> The antigens of the MNS system arise from single nucleotide substitution, unequal crossing over, or gene conversion between the glycoprotein genes (Table 2).

## Glycoprotein A and Glycoprotein B

GPA is the most abundant sialoglycoprotein in the RBC membrane with an estimated  $1 \times 10^6$  copies per RBC.<sup>3-5</sup> GPA consists of 131 amino acids with an approximate molecular weight of 43 kDa [by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)], organized into three domains: an extracellular N-terminal domain of 72 amino acids, a hydrophobic membrane-spanning domain of 23 amino acids, and a C-terminal cytoplasmic domain of 36 amino acids.

GPB is similar to GPA, but consists of 72 amino acids, has an approximate molecular weight of 25 kDa (by SDS-PAGE) and is also organized into three domains: an extracellular N-terminal domain of 44 amino acids, a hydrophobic membrane-spanning domain of 20 amino acids, and a short C-terminal cytoplasmic domain of 8 amino acids. There are an estimated  $2 \times 10^5$  copies of GPB present on the RBC membrane.<sup>4,5</sup>

On intact RBCs, GPA is susceptible to cleavage by trypsin at amino acid residue 31 and 39 but is resistant to  $\alpha$ -chymotrypsin cleavage whereas GPB is resistant to trypsin cleavage but sensitive to  $\alpha$ -chymotrypsin at amino acid residue 32.<sup>3,6</sup> Thus, these proteolytic enzymes are useful in laboratory testing to identify antibodies in the MNS blood group system.

## Function of Glycoprotein A and Glycoprotein B

GPA and GPB contribute most of the carbohydrate on the RBC membrane. The amino-terminal domains of GPA and GPB carry O-glycans while only GPA carries an asparagine-linked-glycan (N-glycan).<sup>5</sup> The O-glycans are smaller molecules than N-glycans and are attached to serine or threonine. In glycoproteins, it is the O-glycans that carry most of the sialic acid and contribute to the net negative charge of the RBC through the high sialic acid content of each glycoprotein. The negative charge keeps RBCs from sticking to each other and to the endothelial cells of the blood vessels.<sup>5,7</sup> The negatively charged glycocalyx also protects the RBC from invasion by bacteria and other pathogens.<sup>8,9</sup> GPA-deficient RBCs are more resistant to invasion by *Plasmodium falciparum* merozoites due to the reduction of sialic acid on the RBCs because sialic acid appears to be essential for adhesion of the parasite to the RBC.<sup>10-14</sup> The sialic acid attached to GPA and GPB has been reported to be the target of the influenza virus<sup>8</sup> and the encephalomyocarditis virus.<sup>15</sup> Moreover, GPA plays the role of chaperone for band 3 transport to the RBC membrane.<sup>16,17</sup>

**Table 1.** Antigens of the MNS blood group system<sup>2</sup>

Antigen	Historical name	ISBT number
M		MNS1
N		MNS2
S		MNS3
s		MNS4
U		MNS5
He	Henshaw	MNS6
Mi <sup>a</sup>	Miltenberger	MNS7
M <sup>c</sup>		MNS8
Vw	Gr, Verweyst	MNS9
Mur	Murrell	MNS10
M <sup>g</sup>	Gilfeather	MNS11
Vr	Verdegaal	MNS12
M <sup>e</sup>		MNS13
Mt <sup>a</sup>	Martin	MNS14
St <sup>a</sup>	Stones	MNS15
Ri <sup>a</sup>	Ridley	MNS16
Cl <sup>a</sup>	Caldwell	MNS17
Ny <sup>a</sup>	Nyberg	MNS18
Hut	Hutchinson	MNS19
Hil	Hill	MNS20
M <sup>r</sup>	Armstrong	MNS21
Far	Kam	MNS22
s <sup>D</sup>	Dreyer	MNS23
Mit	Mitchell	MNS24
Dantu		MNS25
Hop	Hopper	MNS26
Nob	Noble	MNS27
En <sup>a</sup>		MNS28
ENKT	En <sup>a</sup> KT	MNS29
'N'		MNS30
Or	Orriss	MNS31
DANE		MNS32
TSEN		MNS33
MINY		MNS34
MUT		MNS35
SAT		MNS36
ERIK		MNS37
Os <sup>a</sup>		MNS38
ENEP		MNS39
ENEH		MNS40
HAG		MNS41
ENAV	AVIS	MNS42
MARS		MNS43
ENDA	High - GPA-B-A	MNS44
ENEV	High - V62G	MNS45
MNTD	Low - T17R	MNS46

**Table 2.** Molecular mechanisms and associated antigens

Molecular mechanism	Associated antigens
Single nucleotide substitution	GPA: Vr, Mt <sup>a</sup> , Ri <sup>a</sup> , Ny <sup>a</sup> , Or, ERIK, Os <sup>a</sup> , ENEP/HAG, ENAV/MARS GPB: S/s, M <sup>r</sup> , s <sup>D</sup> , Mit
Two or more nucleotide substitution	M/N
Unequal crossing over	St <sup>a</sup> , Dantu, Hil, TSEN, MINY, SAT
Gene conversion	He, Mi <sup>a</sup> , Vw/Hut/ENEH, Mur, M <sup>g</sup> , M <sup>c</sup> , St <sup>a</sup> , Hil, Hop, Nop, DANE, MINY, MUT


**GYP Gene Family**

The genes encoding GPA (*GYPA*) and GPB (*GYPB*) are homologous and are located on the long arm of chromosome 4.<sup>18</sup> Although it may not encode a RBC product, a third homologous gene, *GYPE*, which is adjacent to *GYPB*, can contribute to hybrid genes. The *GYPA* has seven exons, *GYPB* has six exons (of which exon 3 is a pseudoexon or non-coding exon), and *GYPE* has six exons (of which exons 3 and 4 are pseudoexons).<sup>19-22</sup> For each of the *GYP* genes, exon 1 and part of the 5' end of exon 2 encode the leader sequence for the corresponding glycoprotein, exons 2 to 4 encode the extracellular domains, exon 5 encodes the transmembrane domains of each glycoprotein, and exon 6 and part of the 5' end of exon 7 of *GYPA* encode the cytoplasmic domain of GPA (Fig. 1: Modified from Reid ME, 1994).<sup>23</sup>

**Polymorphic Antigens**

*M, N, S, and s antigens*

GPA carries M and N antigens. M has serine and glycine while N has leucine and glutamic acid at position 1 and 5, respectively.<sup>24,25</sup> The first 26 amino acids of GPB are identical to GPA carrying the N



**Fig. 1.** Genomic organization of *GYPA*, *GYPB*, and *GYPE* genes.

antigen.<sup>19,24,26</sup> GPB carries S or s antigens. The Ss polymorphism of GPB depends on a single amino acid substitution at position 29; S has methionine and s has threonine<sup>27</sup> (Table 3).

**Table 3.** Amino acid polymorphisms of GPA and GPB

Glycophorin	Gene	Common variants	Amino acid polymorphisms
GPA	GYPA	GPA <sup>M</sup>	1 Ser, 5 Gly
		GPA <sup>N</sup>	1 Leu, 5 Glu
GPB	GYPB	GPB <sup>S</sup>	29 Met
		GPB <sup>s</sup>	29 Thr

## High-Prevalence Antigens

### U antigen

The U antigen is commonly found in all populations. The U<sup>-</sup> phenotype is found among Blacks and its prevalence in certain regions of Africa is as high as 35 percent.<sup>28</sup> For expression, the U determinant requires the presence of GPB amino acids 33 to 39<sup>29</sup> and possibly an interaction with another membrane protein, the Rh associated glycoprotein (RhAG).<sup>30</sup> The U<sup>-</sup> phenotype is associated with an absence of GPB or with certain altered forms of GPB.<sup>31</sup> U<sup>-</sup> RBCs (except those that are Dantu+ and some Rh<sub>null</sub>/Rh<sub>mod</sub> RBCs) are S-s-. Of S-s- RBCs, approximately 16 percent have weak expression of U antigen (U<sup>var</sup>) encoded by a hybrid GYP gene. Of these U<sup>var</sup> samples approximately 23 percent are He+.<sup>32,33</sup>

### En<sup>a</sup> antigen

Anti-En<sup>a</sup> is a global term used for antibodies that detect high prevalence antigens on GPA. The sensitivity of these antigens to enzyme treatment is dependent on their location on GPA. Thus, En<sup>a</sup> antigens are classified as trypsin sensitive (TS), ficin sensitive (FS), and ficin resistant (FR). En<sup>a</sup> antigens are absent from GPA-deficient RBCs and those carrying certain variants of GPA.<sup>3,5,7,34</sup>

## Genetic Mechanisms Giving Rise to Variant Phenotypes

Variant phenotypes may occur as a consequence of a single amino acid substitution, crossing over, gene conversion, or gene deletion (Table 2). A novel sequence of amino acids exposed on the outside surface of the RBC can result in the expression of novel antigens.

### GYP gene deletions giving rise to null phenotype RBCs

A deletion of GYPA (exon 2 to 7) and GYPB (exon 1) gives rise to the rare En(a-)Fin phenotype and RBCs from these individuals lack GPA and, thus, antigenic determinants associated with GPA.<sup>31,35</sup> Deletion of GYPB (exon 2 to 6) and GYPE (exon 1) precludes production of GPB and RBCs from these individuals have the S-s-U- phenotype.<sup>36</sup> A deletion of GYPA (exon 2 to 7), GYPB (exon 1 to 6) and GYPE (exon 1) results in the M<sup>k</sup>M<sup>k</sup> genotype and RBCs from these individuals lack both GPA and GPB and, thus lack all MNS blood group antigens<sup>20,37</sup> (Table 4).

**Table 4.** Molecular basis of null phenotype RBCs

Null phenotype RBCs	Molecular basis
En(a-)Fin	Deletion of GYPA (exon 2 to 7) and GYPB (exon 1)
S-s-U- (deletion type)	Deletion of GYPB (exon 2 to 6) and GYPE (exon 1)
M <sup>k</sup> M <sup>k</sup>	Deletion of GYPA (exon 2 to 7), GYPB (exon 1 to 6), and GYPE (exon 1)

### Nucleotide substitution


Those antigens in the MNS system that result from a single nucleotide substitution within GYPA or GYPB<sup>31</sup> are listed in Table 5.

### Crossing over and gene conversion

The GYPA, GYPB, and GYPE share more than 95 percent sequence identity, span at least 150 kb of DNA,

**Table 5.** Molecular basis of antigens in the MNS system involving single nucleotide substitution<sup>38</sup>

Antigen	Exon	Nucleotide change	Amino acid change
<b>GPA</b>			
ENEH/Vw/Hut	3	140C>T>A	Thr28Met/Lys
Vr	3	197C>A	Ser47Tyr
Mt <sup>a</sup>	3	230C>T	Thr58Ile
Ri <sup>a</sup>	3	226G>A	Glu57Lys
Ny <sup>a</sup>	3	138T>A	Asp27Glu
Or	3	148C>T	Arg31Trp
ERIK	4	232G>A	Gly59Arg
Os <sup>a</sup>	3	217C>T	Pro54Ser
ENEP/HAG	4	250G>C	Ala65Pro
ENAV/MARS	4	244C>A	Glu63Lys
<b>GPB</b>			
S/s	4	143T>C	Met29Thr
M <sup>v</sup>	2	65C>G	Thr3Ser
s <sup>D</sup>	4	173C>G	Pro39Arg
Mit	4	161G>A	Arg35His



**Fig. 2.** An unequal crossing-over event and gene conversion events between homologous glycoporphin genes on the long arm of chromosome 4 during meiosis.

[Figure is adapted from C.-H. Huang (Huang C-H, Blumenfeld OO. MNSs blood groups and major glycoporphins: Molecular basis for allelic variation. In: Molecular Basis of Human Blood Group Antigens. Cartron J-P, Rouger P (eds). New York: Plenum Press, 1995; p.160.), with permission.]

and are adjacent at the MNS locus in the order of 5'-GYPA-GYPB-GYPE-3'. GYPE probably does not encode a RBC membrane component but it does participate in gene rearrangements resulting in variant alleles. Sequence homology between the glycoporphin genes increases the chance of recombination because of unequal crossing over or gene conversion events (Figure 2: Adapted with permission from Cheng-Han Huang).<sup>31,39</sup>

Unequal crossing over is a mutual exchange of nucleotides between misaligned homologous genes during meiosis; this mechanism occurs between regions of homology with generation of two recombinants in reciprocal arrangement. A chromosome carrying the hybrid GYP(A-B) does not have GYPA and GYPB (Lepore type). In contrast, a chromosome carrying a hybrid GYP(B-A) also has both GYPA and GYPB (Anti-Lepore type).

Gene conversion can occur during the process of DNA repair between homologous genes during meiosis.<sup>31,40</sup> Gene conversion is the transfer of nucleotides from one gene to another gene and does not result in a reciprocal product. Gene conversion

can cause insertion of nucleotides from GYPA into the GYPB or GYPB into the GYPA. As a result of this mechanism, the chromosome carrying a GYP(B-A-B) also carries a GYPA but not GYPB, whereas the chromosome carrying a GYP(A-B-A) also carries a GYPB but not GYPA. During gene conversion, a consensus splice sequence may be altered and a number of recombinant products have been described. These alterations sometimes cause transcription of part of the GYPB pseud exon 3 and hence allow translation of a novel sequence of amino acids.<sup>31</sup> Gene conversion gives rise to hybrid genes that encode novel glycoporphin molecules carrying certain low-prevalence antigens in the MNS blood group system (Table 6).

### Low-Prevalence Antigens

#### He

The He antigen is found in about 3 percent of African Americans but is very rare in Caucasians.<sup>41</sup> Protein sequencing showed that GPHe is identical to GPB except for an alteration at the amino-terminus; the amino acids leucine, threonine, and glutamic acid found in positions 1, 4, and 5 of GPB are replaced by threonine, serine, and glycine, respectively.<sup>42</sup> In GPHe, the presence of a glycine residue at position 5 is recognized by some anti-M. DNA analysis has shown that He antigen is due to gene conversion resulting in a GYP(B-A-B) or a GYP(B-A-ΨB-A) hybrid. In addition to the classic He+S+ and He+s+ variants, four other GYPB variants of GPHe have been described as follows.

GPHe(P2) is characterized by two mutations in GYPB: a C>G change at the 3' end of exon 5, which creates a cryptic acceptor splice site, and a G>T change at position +5 of intron 5, which alters the consensus donor splice site.<sup>43</sup> These two mutations cause skipping of exon 5 and a shift in the open reading frame with chain elongation. Consequently, a portion of the 3' untranslated region is read during protein synthesis, causing GPHe(P2) to have a new transmembrane hydrophobic sequence. This variant does not express the S antigen or the U antigen. GPHe(P2) has not been detected in the RBC membrane; however, these S-s-RBCs are He+<sup>w</sup> because of the expression of low levels

of GPB.He. GPHe(NY) is characterized by a partial deletion of exon 5 that alters the open reading frame and is predicted to encode a protein of 43 amino acids, which has not been demonstrated in the RBC membrane. The S-s- RBCs are He+<sup>w</sup> caused by the expression of low levels of GPB.He.<sup>33</sup>

GPHe(GL) is characterized by two nucleotide changes: a T>G mutation at nucleotide -6 of the acceptor splice in intron 3, which leads to skipping of exon 4, and a C>G mutation in exon 5. The latter point mutation results not only in a predicted Thr>Ser substitution at position 65 but in the creation of a new acceptor splice site; partial inactivation of the normal splice site results in four different cDNAs. The full-length transcript GPHe-1, which is equivalent to GPB in molecular size, contains a Thr>Ser substitution at position 65 and encodes He, S, and U antigens. Transcript GPHe-2 codes for a polypeptide with an intact transmembrane segment but, because of the deficiency of exon 4, the encoded protein lacks the sequence defining the S and U antigens as well as the cleavage sites of  $\alpha$ -chymotrypsin.<sup>3</sup> Transcripts GPHe-3 and GPHe-4 are low-level transcripts with major deletions which probably prevent insertion of their putative protein products into the membrane.<sup>44</sup>

GP.Cal is an example of a gene conversion event resulting in a GP(B-A- $\Psi$ B-A) hybrid that carries both He and St<sup>a</sup> antigens. The *GYP*A recombination site is in exon 2; the mature protein, after cleavage of the leader peptide, is GP(A-A). *GYP*B also contributes the pseudo-exon, which is out-spliced.<sup>45</sup> The 5' portion of GP.Cal is similar to GP.He with a GP(B-A-B) arrangement, whereas its 3' portion has a GP(B-A) configuration identical to the GPSt<sup>a</sup>.<sup>46</sup>

### SAT

The SAT antigen is associated with two different glycoprotein isoforms.<sup>47</sup> GP.TK is a GP(A-B) hybrid composed of exons 1 to 4 of *GYP*A<sup>N</sup> and exons 5 to 6 of *GYP*B.<sup>48</sup> This transcript encodes 104 amino acids with a hexapeptide sequence "Ser-Glu-Pro-Ala-Pro-Val" at positions 69 to 74 produced by the junction between GPA and GPB, and encodes the SAT antigen. GPSAT is associated with a *GYP*A-B-A hybrid gene which encodes a GPA-B-A hybrid (Table 6). This variant is characterized by an insert, between exon 4 of *GYP*A and exon 5 of *GYP*B, of nine bases (three amino acids) originating from the 5' end of exon 5 of *GYP*B. The tripeptide sequence "Ala-Pro-Val" inserted into the GPA molecule creates the SAT-specific sequence.<sup>49</sup>

**Table 6.** Hybrid glycoprotein molecules, phenotypes, and associated low prevalence antigen<sup>38</sup>

Molecular basis	Glycoprotein	Phenotype symbol	Antigens associated with hybrid
<i>GYP</i> (A-B)	GP(A-B)	GP.Hil (Mi.V)	Hil, MINY
		GP.JL (Mi.XI)	TSEN, MINY
		GP.TK	SAT
<i>GYP</i> (B-A)	GP(B-A)	GP.Sch (M <sup>c</sup> )	St <sup>a</sup>
		GP.Dantu	Dantu (see Table 7)
<i>GYP</i> (A-B-A)	GP(A-B-A)	GP.M <sup>e</sup>	M <sup>e</sup>
		GP.KI	Hil
	GP(A-B)	GPSAT	SAT
<i>GYP</i> (B-A-B)	GP(B-A-B)	GP.Mur (Mi.III)	Mi <sup>a</sup> , Mur, MUT, Hil, MINY
		GP.Bun (Mi.VI)	Mi <sup>a</sup> , Mur, MUT, Hop, Hil, MINY
		GP.HF (Mi.X)	Mi <sup>a</sup> , MUT, Hil, MINY
		GP.Hop (Mi.IV)	Mi <sup>a</sup> , Mur, MUT, Hop, TSEN, MINY
	GP(B-A-B)	GPHe; (P2, GL)	He
<i>GYP</i> (B-A- $\Psi$ B-A)	GP(A-A)	GP.Cal	He, St <sup>a</sup>
<i>GYP</i> (A- $\Psi$ B-A)	GP(A-B-A)	GP.Vw (Mi.I)	Mi <sup>a</sup> , Vw
		GP.Hut (Mi.II)	Mi <sup>a</sup> , Hut, MUT
		GP.Nob (Mi.VII)	Nob
		GP.Joh (Mi.VIII)	Nob, Hop
		GP.Dane (Mi.IX)	Mur, DANE
		GP(A-A)	GP.Zan (M <sup>c</sup> )
<i>GYP</i> A 179G>A	GPA	GP.EBH	ERIK (from transcript 1) See text
		GP.EBH	St <sup>a</sup> (from transcript 2) See text
<i>GYP</i> (A- $\Psi$ E-A)	GP(A-A)	GP.Mar	St <sup>a</sup>

### Dantu

GP.Dantu is encoded by a *GYP*(B-A) hybrid. This hybrid gene consists of exon 1, exon 2, pseudoexon 3, exon 4 of *GYP*B, and exons 5 to 7 of *GYP*A. There are four types of Dantu phenotype, designated NE, MD, Ph, and JO variants (Table 7). The MD hybrid gene is flanked by *GYP*A and *GYP*B, suggesting that this type originated from a single unequal crossing-over event.<sup>50</sup> The NE and Ph variants contain a *cis* *GYP*A but lack a *GYP*B.<sup>51</sup> In the case of NE, the *GYP*(B-A) hybrid gene is duplicated; thus NE and Ph variants can be distinguished by the ratio of GP.Dantu [GP(B-A) hybrid] to GPA.<sup>52</sup> RBCs with the JO variant have only one-half the normal levels of GPA, thus leading to the assumption that this variant may contain a GP(A-B-A) hybrid molecule and an unchanged *GYP*B rather than an unchanged *GYP*A and GP(B-A) hybrid.<sup>53</sup>

**Table 7.** Mechanism, ethnicity, and occurrence of Dantu phenotypes

Dantu phenotypes	Mechanism	Ethnicity	Occurrence (relative)
NE	<i>GYP(A-GYP(B-A)-GYP(B-A))</i>	Black	Most (common phenotype)
MD	<i>GYP(A-GYP(B-A)-GYPB)</i>	White	Rare (1 proband)
Ph	<i>GYP(A-GYP(B-A))</i>	Black	Rare (1 proband)
Jo	<i>GYP(B-A)-GYPB</i>	White	Rare (1 proband)

*M<sup>s</sup>*

The M<sup>s</sup> antigen is associated with a *GYP(A-B-A)* hybrid; it has the same amino acids at positions 1 (leucine) and 5 (glutamic acid) as *GYP(A)<sup>N</sup>* but threonine in position 4 is substituted by an asparagine.<sup>54</sup> RBCs with GP.M<sup>s</sup> do not react with anti-M and anti-N but do react with anti-M<sup>s</sup>.<sup>55</sup> M<sup>s</sup>+ RBCs react with anti-DANE because of the amino acids Asn-Glu-Val at positions 4, 5, and 6 are thought to be part of the DANE epitope.<sup>56,57</sup>

*St<sup>a</sup> (Stones)*

The St<sup>a</sup> antigen is most commonly associated with a *GYP(B-A)* hybrid but also can be associated with *GYP(A-B-A)* or *GYP(A-E-A)* hybrid genes.<sup>38</sup>

GPSch (M<sup>r</sup>) is encoded by a *GYP(B-A)* hybrid. The hybrid gene arose from a single unequal crossing over between misaligned *GYP(A)* and *GYP(B)*. This misalignment led to *GYP(B)* exons 1 to pseudoexon 3 being joined to exons 4 to 7 of *GYP(A)*. The St<sup>a</sup> epitope is determined by the amino acid sequence of the junction of exon 2 to exon 4 of either GPB or GPA. The molecule is composed of amino acids 1 to 26 of GPB and amino acids 59 to 131 of GPA.

GPZan (M<sup>z</sup>) is encoded by a *GYP(A-ΨB-A)* hybrid. The GPZan phenotype is characterized by the co-transmission of M and St<sup>a</sup>.<sup>58</sup> The homologous segment of *GYP(B)* pseudoexon 3 replaces exon 3 and the 5' end of intron 3 of *GYP(A)*, introducing the defective donor splice site of the pseudoexon. Thus, the encoded glycoprotein consists of GPA lacking the amino acids encoded by exon 3.

GPB<sup>H</sup> is another St<sup>a</sup> carrying glycoprotein, which arises by a single nucleotide substitution at position 179 in *GYP(A)*. This variant is caused by a G>A mutation in the 3' end of exon 3,<sup>39</sup> which creates a Gly>Arg substitution at amino acid position 59. The mutation also affects pre-mRNA splicing because of the partial inactivation of the adjacent 5' donor splice site. The full-length transcript (transcript 1) encodes a variant GPA molecule with the arginine substitution at amino acid position 59 defining the ERIK antigen, whereas the shorter transcript (transcript 2) lacks exon 3 and carries the St<sup>a</sup> antigen.<sup>58,59</sup>

GPMar is encoded by a *GYP(A-ΨE-A)* hybrid that arose from a homologous DNA transfer from *GYPE* to *GYP(A)*. This *GYPE* segment covers pseudoexon 3 and extends to the defective donor splice site mutated by the G>A transition at +1 position of GT dinucleotide, which abolishes a donor splice site as well as the expression of exon 3 of GPA.<sup>60</sup> *GYPMar* gene is apparently identical to the *GYPZan* in the mode of gene conversion and in the resulting glycoprotein.

*The so-called or obsolete Miltenberger subsystem*

A number of low-prevalence antigens in the MNS blood group system were for many years grouped together in the Miltenberger (Mi.) subsystem.<sup>61</sup> Originally, RBCs reactive with the anti-Mi<sup>a</sup> serum were classified into four classes on the basis of their different reactions with four type sera called Verweyst (Vw), Miltenberger (Mi<sup>a</sup>), Murrell (Mur), and Hill (Hil).<sup>62</sup> Some of the classes of Miltenberger did not react with anti-Mi<sup>a</sup> but reacted with one or more of the other three specific antisera, e.g., GP.Hil (Mi.V) RBCs reacted with anti-Mi<sup>a</sup> but did not react with anti-Hil.<sup>63</sup> The Miltenberger subsystem grew to 11 classes, which were defined by one or more determinants reacting with type-specific antisera (Table 8).<sup>38,64</sup>


As the complexity of the Miltenberger subsystem increased, further expansion no longer seemed feasible, desirable, or relevant. A notation was introduced to replace the classification of MNS variants into the increasingly complicated Miltenberger subsystem. In this notation, the serologically specified phenotypes are defined by characteristic glycoprotein variants (GP for the glycoprotein and GYP for the gene) with the abbreviated name of the propositus in whom the variant has been described, e.g., Mi.V becomes GP.Hil and the encoding gene is referred to as *GYP.Hil*. The Miltenberger subsystem will not be expanded further and is now considered obsolete.<sup>65</sup> The molecular basis of antigens in the obsolete Miltenberger subsystem can be placed into the following categories.

1. Glycoprotein A-B hybrids: GP(A-B)

GP.Hil (Mi.V) and GP.JL (Mi.XI) are each encoded by a *GYP(A-B)* hybrid gene (Fig. 3-D). The *GYP(A)* to *GYP(B)* junction in the *GYP.Hil* gene is located at the 5' end of the intron 3 of *GYP(A)*, whereas in *GYP.JL* the junction occurs at the 3' end of intron 3 and includes 7 nucleotides (nts) of exon 4 of *GYP(B)*. The allele responsible for GP.Hil encodes s antigen, travels with either Ms or Ns, and expresses Hil and MINY

**Table 8.** GP classification and associated antigens of the obsolete Miltenberger subsystem<sup>38</sup>

GP.	Mi.Reaction of RBCs with antiserum											
	Classes	Mi <sup>a</sup>	Vw	Mur	Hil	Hut	MUT	Hop	Nob	DANE	MINY	TSEN
GP.Vw	Mi.I	+	+	-	-	-	-	-	-	-	-	-
GP.Hut	Mi.II	+	-	-	-	+	+	-	-	-	-	-
GP.Mur	Mi.III	+	-	+	+	-	+	-	-	-	+	-
GP.Hop	Mi.IV	+	-	+	-	-	+	+	-	-	+	+
GP.Hil	Mi.V	-	-	-	+	-	-	-	-	-	+	-
GP.Bun	Mi.VI	+	-	+	+	-	+	+	-	-	+	-
GP.Nob	Mi.VII	-	-	-	-	-	-	-	+	-	-	-
GP.Joh	Mi.VIII	-	-	-	-	-	-	+	+	-	-	-
GP.Dane	Mi.IX	-	-	+	-	-	-	-	-	+	-	-
GP.HF	Mi.X	+	-	-	+	-	+	-	-	-	+	-
GP.JL	Mi.XI	-	-	-	-	-	-	-	-	-	+	+



**Fig. 3.** Genomic organization of some glycoprotein hybrids.  
 (□), GYP(A); (■), GYP(B); and (▒), pseudoexon B

antigens,<sup>22,66,67</sup> whereas GP.JL expresses an altered S, a weak M, TSEN, and MINY antigens.<sup>67-71</sup> No example of GP.Hil phenotype was found in testing 50,000 English donors, but GP.Hil was found with a frequency of 1 in 2000 in one survey of Swiss blood donors.<sup>72</sup>

**2. Glycophorin A-B-A hybrids: GP(A-B-A)**

GP.Vw (Mi.I), GP.Hut (Mi.II), GP.Nob (Mi.VII), GP.Joh (Mi.VIII), and GP.Dane (Mi.IX) are each encoded by a *GYP(A-B-A)* hybrid (Fig. 3-II). In these hybrid genes, inserts of different short portions of the pseudoexon of *GYPB* replace the same number of nucleotides in exon 3 of *GYPA*. The small inserts range from 1 to 16 bp and do not alter the open reading frame or disrupt the splice sites. Thus, the short part of the pseudoexon is translated in this hybrid.

The insert encoding GP.Vw and GP.Hut variants results in an amino acid polymorphism at position 28; the threonine present in GPA is changed to methionine in the case of GP.Vw<sup>73</sup> and to lysine in the case of GP.Hut. GP.Vw and GP.Hut phenotype RBCs are recognized by anti-Vw and anti-Hut, respectively. The allele responsible for GP.Vw usually travels with Ns, NS, or MS whereas GP.Hut travels with MS or Ns. The highest prevalence of GP.Vw phenotype, 1.43 percent, was found in southeastern Switzerland.<sup>41</sup>

RBCs with GP.Nob express the Nob antigen. Structural analysis of GP.Nob showed that it differs from GPA at amino acid positions 49 and 52; the arginine at position 49 in GPA is substituted by threonine and the tyrosine at position 52 is replaced by serine because of ten nucleotides in exon 3 of *GYPA* (nt 67-76) that have been replaced by the corresponding sequence of the GPB pseudoexon.<sup>74,75</sup> The GP.Nob phenotype has been only found in white donors; three positive reactors with the Raddon serum were found in tests on 4929 random group O blood donors at Bristol, England, a frequency of 0.06 percent.<sup>76</sup> GP.Nob is associated with Ms and MS.

GP.Joh closely resembles GP.Nob but has the Hop antigen as well as the Nob antigen. The altered GPA of

GPJoh differs from GPNob by having only the arginine to threonine substitution at amino acid position 49.<sup>77</sup> The frequency of GPJoh is unknown. The *GYPJob* traveled with Ns in the families of the two known *propositi*.

RBCs carrying GPDane express Mur and DANE antigens. In GPDane, exon 3 of *GYP A* (codons 35–41) is replaced by the corresponding sequence of the *GYP B* pseudoexon.<sup>78</sup> As a consequence of this gene conversion event, the hepta peptide sequence of GPA, <sup>35</sup>Ala-Ala-Thr-Pro-Arg-Ala-His<sup>41</sup>, is changed to the hexapeptide sequence <sup>35</sup>Pro-Ala-His-Thr-Ala-Asn<sup>40</sup>. GPDane has a prevalence of 0.43 percent in Danes. In the four Danish *propositi*, *GYP Dane* was inherited with *MS*.<sup>56</sup>

### 3. Glycophorin B-A-B hybrids: GP(B-A-B)

GMur (Mi.III), GHop (Mi.IV), GBun (Mi.VI), and GHF (Mi.X) are each encoded by a *GYP(B-A-B)* hybrid (Fig. 3-III).

GMur RBCs are Mur+, Hil+ and MINY+ and the allele responsible for GMur always travels with s antigen, either as Ms or Ns. GBun is almost identical to GMur but GBun cells are Hop+ and the allele responsible for GBun was aligned with Ms. Both GMur and GBun are encoded by a *GYP B*<sup>s</sup> but differ in the length of the GPB pseudoexon insert (55 bp for GMur and 131 bp for GBun).<sup>79</sup> Because this segment comprises a portion of both exon 3 and intron 3, which carries a functional 5' splicing signal, the rearrangement results in the expression of a normally unexpressed *GYP B* pseudoexon sequence. The *GYP Bun* gene differs from the *GYP Mur* gene by only one nucleotide in the coding sequence. This results in a predicted arginine (GMur) or threonine (GBun) at position 48. GMur and GBun are rare in Caucasians but GMur has a prevalence between 5 and 10 percent in some Asian populations,<sup>40,80,81</sup> 9.6 percent in Thais, and 7.3 percent in Taiwanese.<sup>82</sup>

GHop, which expresses TSEN but not Hil, is identical to GBun. The allele responsible for GHop always travels with S, whereas the allele for GBun always carries the s antigen.<sup>61,83</sup>

GHF is characterized by M and an unusually strong s antigen as well as by its reactivity with anti-Hil and anti-MINY. This glycophorin hybrid is similar to GMur and GBun.<sup>84</sup> In GHF, a 98-bp insert from exon 3 of *GYP A* creates a *GYP(B-A-B)* hybrid, which encodes a peptide differing from GMur by five amino acid residues and from GBun by six amino acid residues.

## Conclusion

The MNS system is a complex blood group system consisting of more than 40 antigens on GPA and GPB, or on hybrid glycophorin molecules. It is second only to the Rh blood group system in its complexity. The antigens of the MNS blood group system arise from single nucleotide substitution, unequal crossing over, gene conversion, or both between the glycophorin genes. Some of these molecular mechanisms occur as a consequence of misalignment of the chromosomes carrying the glycophorin genes during meiosis. This is possible because the glycophorin family of genes is homologous and adjacent on the chromosome.

## Acknowledgments

I wish to thank Oytip Nathalang, PhD, from the Department of Pathology, Phramongkutklo College of Medicine; Sasitorn Bejrachandra, MD, from the Department of Transfusion Medicine, Faculty of Medicine, Siriraj Hospital; Srisurang Tantimavanich, PhD, from the Department of Clinical Microbiology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand; and Marion Reid and Christine Lomas-Francis from the Laboratory of Immunohematology, New York Blood Center, for critically reviewing the manuscript. I also thank Robert Ratner for preparing the manuscript and figures. The work was funded by the University Development Commissions (UDC) of Ministry of University Affairs, Thailand.

## References

1. Landsteiner K, Levine P. Further observations on individual differences of human blood. *Proc Soc Exp Biol Med* 1927;24:941.
2. Daniels GL, Fletcher A, Garratty G, et al. Blood group terminology 2004. *Vox Sang* 2004;87:316.
3. Dahr W. Immunochemistry of sialoglycoproteins in human red blood cell membranes. In: recent advances in blood group biochemistry. Vengelen-Tyler V, Judd WJ (eds). Arlington, VA: American Association of Blood Banks, 1986;23-65.
4. Gardner B, Parsons SF, Merry AH, Anstee DJ. Epitopes on sialoglycoprotein alpha: evidence for heterogeneity in the molecule. *Immunol* 1989;68:283-9.
5. Anstee DJ. The nature and abundance of human red cell surface glycoproteins. *J Immunogenet* 1990;17:219-25.



6. Judson PA, Anstee DJ. Comparative effect of trypsin and chymotrypsin on blood group antigens. *Med Lab Sci* 1977;34:1-6.
7. Blanchard D. Human red cell glycoporphins: biochemical and antigenic properties. *Transf Med Rev* 1990;4:170-86.
8. Lublin DM. Functional roles of blood group antigens. In: molecular and functional aspects of blood group antigens. Silberstein LE (ed). Bethesda, MD: American Association of Blood Banks, 1995;163-92.
9. Moulds JM, Nowicki S, Moulds JJ, Nowicki BJ. Human blood groups: incidental receptors for viruses and bacteria. *Transfusion* 1996;36:362-74.
10. Cartron J-P, Prou O, Lulier M, Soulier JP. Susceptibility to invasion by *Plasmodium falciparum* of some human erythrocytes carrying rare blood group antigens. *Br J Haematol* 1983;55:639-47.
11. Chasis JA, Mohandas N, Shohet SB. Erythrocyte membrane rigidity induced by glycoporphin A-ligand interaction. Evidence for a ligand-induced association between glycoporphin A and skeletal proteins. *J Clin Invest* 1985;75:1919-26.
12. Pasvol G, Chasis JA, Mohandas N, et al. Inhibition of malarial parasite invasion by monoclonal antibodies against glycoporphin A correlates with reduction in red cell membrane deformability. *Blood* 1989;74:1836-43.
13. Hadley TJ. Invasion of erythrocytes by malaria parasites: a cellular and molecular overview. *Annual Review of Microbiology* 1986;40:451-77.
14. Orlandi PA, Klotz FW, Haynes JD. A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of *Plasmodium falciparum* recognizes the terminal Neu5Ac(alpha 2-3)Gal-sequences of glycoporphin A. *J Cell Biol* 1992;116:901-9.
15. Allaway GP, Burness AT. Site of attachment of encephalomyocarditis virus on human erythrocytes. *J Virol* 1986;59:768-70.
16. Groves JD, Tanner MJ. Glycoporphin A facilitates the expression of human band 3-mediated anion transport in *Xenopus* oocytes. *J Biol Chem* 1992;267:22163-70.
17. Groves JD, Tanner MJ. The effects of glycoporphin A on the expression of the human red cell anion transporter (band 3) in *Xenopus* oocytes. *J Membr Biol* 1994;140:81-8.
18. Lögdberg L, Reid ME, Lamont RE, Zelinski T. Human blood group genes 2004: chromosomal locations and cloning strategies. *Transf Med Rev* 2005;19:45-57.
19. Kudo S, Fukuda M. Structural organization of glycoporphin A and B genes: glycoporphin B gene evolved by homologous recombination at Alu repeat sequences. *Proc Natl Acad Sci USA* 1989;86:4619-23.
20. Vignal A, Rahuel C, London J, et al. A novel gene member of the human glycoporphin A and B gene family. Molecular cloning and expression. *Eur J Biochem* 1990;191:619-25.
21. Kudo S, Fukuda M. Identification of a novel human glycoporphin, glycoporphin E, by isolation of genomic clones and complementary DNA clones utilizing polymerase chain reaction. *J Biol Chem* 1990;265:1102-10.
22. Vignal A, London J, Rahuel C, Cartron J-P. Promoter sequence and chromosomal organization of the genes encoding glycoporphins A, B and E. *Gene* 1990;95:289-93.
23. Reid ME. Some concepts relating to the molecular genetic basis of certain MNS blood group antigens. *Transf Med* 1994;4:99-111.
24. Dahr W. Serology, genetics and chemistry of the MNS blood group system. *Rev Fr Transfus Immunohematol* 1981;24:85-95.
25. Siebert PD, Fukuda M. Isolation and characterization of human glycoporphin A cDNA clones by a synthetic oligonucleotide approach: nucleotide sequence and mRNA structure. *Proc Natl Acad Sci USA* 1986;83:1665-9.
26. Siebert PD, Fukuda M. Molecular cloning of a human glycoporphin B cDNA: Nucleotide sequence and genomic relationship to glycoporphin A. *Proc Natl Acad Sci USA* 1987;84:6735-9.
27. Dahr W, Beyreuther K, Steinbach H, et al. Structure of the Ss blood group antigens, II: a methionine/threonine polymorphism within the N-terminal sequence of the Ss glycoprotein. *Hoppe-Seyler's Z Physiol Chem* 1980;361:895-906.
28. Lowe RF, Moores PP. S-s-U-red cell factor in Africans of Rhodesia, Malawi, Mozambique and Natal. *Hum Hered* 1972;22:344-50.
29. Dahr W, Kordowicz M, Moulds J, et al. Characterization of the Ss sialoglycoprotein and its antigens in Rh<sub>null</sub> erythrocytes. *Blut* 1987;54:13-24.

30. Mallinson G, Anstee DJ, Avent ND, et al. Murine monoclonal antibody MB-2D10 recognizes Rh-related glycoproteins in the human red cell membrane. *Transfusion* 1990;30:222-5.
31. Huang C-H, Blumenfeld OO. MNSs blood groups and major glycoproteins: Molecular basis for allelic variation. In: molecular basis of human blood group antigens. Cartron J-P, Rouger P (eds). New York: Plenum Press, 1995;153-88.
32. Reid ME, Storry JR, Ralph H, et al. Expression and quantitative variation of the low incidence blood group antigen He on some S-s- RBCs. *Transfusion* 1996;36:719-24.
33. Storry JR, Reid ME, Fetis S, Huang C-H. Mutations in *GYPB* exon 5 drive the S-s-U+var phenotype in persons of African descent: Implications for transfusion. *Transfusion* 2003;43:1738-47.
34. Tanner MJ, Anstee DJ. The membrane change in En(a-) human erythrocytes. Absence of the major erythrocyte sialoglycoprotein. *Biochem J* 1976; 153:271-7.
35. Gahmberg CG, Myllyla G, Leikola J, et al. Absence of the major sialoglycoprotein in the membrane of human En(a-) erythrocytes and increased glycosylation of band 3. *J Biol Chem* 1976;251: 6108-16.
36. Huang C-H, Johe K, Moulds JJ, et al.  $\delta$  glycoprotein (glycophorin B) gene deletion in two individuals homozygous for the S-s-U- blood group phenotype. *Blood* 1987;70:1830-5.
37. Tate CG, Tanner MJ, Judson PA, Anstee DJ. Studies on human red-cell membrane glycoprotein A and glycoprotein B genes in glycoprotein-deficient individuals. *Biochem J* 1989;263:993-6.
38. Reid ME, Lomas-Francis C. Blood group antigen factsbook. 2nd ed. San Diego, CA: Academic Press, 2003.
39. Huang C-H, Reid ME, Blumenfeld OO. Exon skipping caused by DNA recombination that introduces a defective donor splice site into the human glycoprotein A gene. *J Biol Chem* 1993; 268:4945-52.
40. Maizels N. Might gene conversion be the mechanism of somatic hypermutation of mammalian immunoglobulin genes? *Trends Genet* 1989;5:4-8.
41. Race RR, Sanger R. Blood groups in man. 6th ed. Oxford: Blackwell Scientific Publications, 1975.
42. Dahr W, Kordowicz M, Judd WJ, et al. Structural analysis of the Ss sialoglycoprotein specific for Henshaw blood group from human erythrocyte membranes. *Eur J Biochem* 1984;141:51-5.
43. Huang C-H, Reid ME, Blumenfeld OO. Remodeling of the transmembrane segment in human glycoprotein by aberrant RNA splicing. *J Biol Chem* 1994;269:10804-12.
44. Huang C-H, Blumenfeld OO, Reid ME, et al. Alternative splicing of a novel glycoprotein allele GPhE(GL) generates two protein isoforms in the human erythrocyte membrane. *Blood* 1997;90: 391-7.
45. Huang C-H, Lomas C, Daniels G, Blumenfeld OO. Glycoprotein He(St<sup>a</sup>) of the human red blood cell membrane is encoded by a complex hybrid gene resulting from two recombinational events. *Blood* 1994;83:3369-76.
46. Huang C-H, Blumenfeld OO. Multiple origins of the human glycoprotein St<sup>a</sup> gene. Identification of hot spots for independent unequal homologous recombinations. *J Biol Chem* 1991;266:23306-14.
47. Daniels GL, Green CA, Okubo Y, et al. SAT, a 'new' low frequency blood group antigen, which may be associated with two different MNS variants. *Transf Med* 1991;1:39-45.
48. Huang C-H, Reid ME, Okubo Y, et al. Glycoprotein SAT of the human erythrocyte membrane is specified by a hybrid gene reciprocal to glycoprotein Dantu gene. *Blood* 1995;85:2222-7.
49. Uchikawa M, Tsuneyama H, Wang L, et al. A novel amino acid sequence result in the expression of the MNS related private antigen, SAT (abstract). *Vox Sang* 1994;67(S2):116.
50. Dahr W, Pilkington PM, Reinke H, et al. A novel variety of the Dantu gene complex (DantuMD) detected in a Caucasian. *Blut* 1989;58:247-53.
51. Huang C-H, Blumenfeld OO. Characterization of a genomic hybrid specifying the human erythrocyte antigen Dantu: Dantu gene is duplicated and linked to a  $\delta$  glycoprotein gene deletion. *Proc Natl Acad Sci USA* 1988;85:9640-4.
52. Tanner MJ, Anstee DJ, Mawby WJ. A new human erythrocyte variant (Ph) containing an abnormal membrane sialoglycoprotein. *Biochem J* 1980; 187:493-500.
53. Merry AH, Hodson C, Thomson E, et al. The use of monoclonal antibodies to quantify the levels of sialoglycoproteins alpha and delta and variant sialoglycoproteins in human erythrocyte membranes. *Biochem J* 1986;233:93-8.

54. Furthmayr H, Metaxas MN, Metaxas-Buhler M. Mg and Mc: Mutations within the amino-terminal region of glycoprotein A. *Proc Natl Acad Sci USA* 1981;78:631-5.
55. Metaxas-Buhler M, Cleghorn TE, Romanski J, Metaxas MN. Studies on the blood group antigen Mg. II. Serology of Mg. *Vox Sang* 1966;11:170-83.
56. Skov F, Green C, Daniels G, et al. Miltenberger class IX of the MNS blood group system. *Vox Sang* 1991;61:130-6.
57. Green C, Daniels G, Skov F, Tippett P. Mg+ MNS blood group phenotype: Further observations. *Vox Sang* 1994;66:237-41.
58. Huang C-H, Reid M, Daniels G, Blumenfeld OO. Alteration of splice site selection by an exon mutation in the human glycoprotein A gene. *J Biol Chem* 1993;268:25902-8.
59. Daniels GL, Green CA, Poole J, et al. ERIK, a low-frequency red cell antigen of the MNS blood group system associated with St<sup>a</sup>. *Transf Med* 1993;3:129-35.
60. Huang CH, Chen Y, Blumenfeld OO. A novel St<sup>a</sup> glycoprotein produced via gene conversion of pseudoexon III from glycoprotein E to glycoprotein A gene. *Human Mutation* 2000;15:533-40.
61. Cleghorn TE. A memorandum on the Miltenberger blood groups. *Vox Sang* 1966;11:219-22.
62. Wallace J, Milne GR, Mohn J, et al. Blood group antigens Mi<sup>a</sup> and Vw and their relation to the MNSs system. *Nature* 1957;179:478.
63. Crossland JD, Pepper MD, Giles CM, Ikin EW. A British family possessing two variants of the MNSs blood group system, Mv and a new class within the Miltenberger complex. *Vox Sang* 1970;18:407-13.
64. Giles CM. Serological activity of low frequency antigens of the MNSs system and reappraisal of the Miltenberger complex. *Vox Sang* 1982;42:256-61.
65. Tippett P, Reid ME, Poole J, et al. The Miltenberger subsystem: is it obsolescent? *Transf Med Rev* 1992;6:170-82.
66. Vignal A, Rahuel C, el Maliki B, et al. Molecular analysis of glycoprotein A and B gene structure and expression in homozygous Miltenberger class V (Mi. V) human erythrocytes. *Eur J Biochem* 1989;184:337-44.
67. Huang C-H, Blumenfeld OO. Identification of recombination events resulting in three hybrid genes encoding human MiV, MiV(J.L.), and St<sup>a</sup> glycoproteins. *Blood* 1991;77:1813-20.
68. Johe KK, Smith AJ, Vengelen-Tyler V, Blumenfeld OO. Amino acid sequence of an  $\alpha$ - $\delta$ -glycoprotein hybrid. A structure reciprocal to St<sup>a</sup>  $\delta$ - $\alpha$ -glycoprotein hybrid. *J Biol Chem* 1989;264:17486-93.
69. Kudo S, Chagnovich D, Rearden A, et al. Molecular analysis of a hybrid gene encoding human glycoprotein variant Miltenberger V-like molecule. *J Biol Chem* 1990;265:13825-9.
70. Reid ME, Moore BP, Poole J, et al. TSEN: A novel MNS-related blood group antigen. *Vox Sang* 1992;63:122-8.
71. Reid ME, Poole J, Green C, et al. MINY: A novel MNS-related blood group antigen. *Vox Sang* 1992;63:129-32.
72. Metaxas MN, Metaxas-Buhler M, Heiken A, et al. Further examples of Miltenberger class V, one of them inherited with a depressed M antigen. *Vox Sang* 1972;23:420-8.
73. Huang C-H, Spruell P, Moulds JJ, Blumenfeld OO. Molecular basis for the human erythrocyte glycoprotein specifying the Miltenberger class I (MiI) phenotype. *Blood* 1992;80:257-63.
74. Dahr W, Beyreuther K, Moulds JJ. Structural analysis of the major human erythrocyte membrane sialoglycoprotein from Miltenberger class VII cells. *Eur J Biochem* 1987;166:27-30.
75. Laird-Fryer B, Moulds JJ, Dahr W, et al. Anti-En<sup>a</sup>FS detected in the serum of an MiVII homozygote. *Transfusion* 1986;26:51-6.
76. Webb AJ, Giles CM. Three antibodies of the MNSs system and their association with the Miltenberger complex of antigens. II. Raddon and Lane sera. *Vox Sang* 1977;32:274-6.
77. Dahr W, Vengelen-Tyler V, Dybkjaer E, Beyreuther K. Structural analysis of glycoprotein A from Miltenberger class VIII erythrocytes. *Biol Chem Hoppe Seyler* 1989;370:855-9.
78. Huang C-H, Skov F, Daniels G, et al. Molecular analysis of human glycoprotein MiIX gene shows a silent segment transfer and untemplated mutation resulting from gene conversion via sequence repeats. *Blood* 1992;80:2379-87.
79. Huang C-H, Blumenfeld OO. Molecular genetics of human erythrocyte MiIII and MiVI glycoproteins. Use of a pseudoexon in construction of two  $\delta$ - $\alpha$ - $\delta$  hybrid genes resulting in antigenic diversification. *J Biol Chem* 1991;266:7248-55.

80. Chandanayingyong D, Pejrachandra S. Studies on the Miltenberger complex frequency in Thailand and family studies. *Vox Sang* 1975;28:152-5.
81. Poole J, King MJ, Mak KH, et al. The MilIII phenotype among Chinese donors in Hong Kong: immunochemical and serological studies. *Transf Med* 1991;1:169-75.
82. Shih MC, Yang LH, Wang NM, Chang JG. Genomic typing of human red cell miltenberger glycoporphins in a Taiwanese population. *Transfusion* 2000;40:54-61.
83. Storry JR, Poole J, Condon J, Reid ME. Identification of a novel hybrid glycoporphin gene encoding GP.Hop. *Transfusion* 2000;40:560-5.
84. Huang C-H, Kikuchi M, McCreary J, Blumenfeld OO. Gene conversion confined to a direct repeat of the acceptor splice site generates allelic diversity at human glycoporphin (*GYP*) locus. *J Biol Chem* 1992;267:3336-42.

---

*P. Palacajornsuk, Department of Clinical Microbiology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, and Laboratory of Immunochemistry, Lindsley F. Kimball Research Institute, New York Blood Center, New York City, New York.*